UNSPSC 51291510: Fezolamine

This classification denotes an antidepressant agent with the molecular formula C20H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1133E05F6C chemically known as 1-(3-(dimethylamino)propyl)-3,4-diphenylpyrazole but generally known as fezolamine, which bears US NIH Compound Identifier 54567. European Medicines Agency schedules Fezolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07620MIG.

UNSPSC 51291510 Fezolamine, a Commodity code, nominally encompasses a single pharmaceutical compound but shows minimal relevant recent activity under this specific code designation. State and local procurement activity tagged to this code actually centers on broader pharmaceutical procurement — generic multi-source drugs, naloxone, drug deactivation systems, and direct-to-manufacturer prescription programs — rather than fezolamine as a discrete product line. The issuing bodies soliciting under related pharmaceutical codes include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The scope reflects state and local demand for pharmaceutical supply chain management, including annual replenishment of naloxone and drug deactivation systems for community health initiatives, competitive bidding for generic pharmaceuticals through authorized wholesaler networks, and exploratory procurement to establish direct relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager intermediaries.

Geographic activity centers on Florida, Texas, and Minnesota, with cooperative purchasing expanding reach across multiple participating states. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) to assess vendor capability for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract awards effective July 1, 2026. The fezolamine code itself shows no discrete recent solicitations and appears misaligned with current state and local pharmaceutical procurement activity.